The scrip declined 6 per cent to Rs 736.10 on the BSE.
On the NSE, shares tanked 5.84 per cent to Rs 736.40.
The US Food and Drug Administration (USFDA) carried out the inspection at the plant from May 6 to May 15, Lupin said in a statement Wednesday.
"The inspection at the Aurangabad facility closed with three observations. The company is confident of addressing them satisfactorily," it added.
Lupin Wednesday posted consolidated profit after tax of Rs 296.37 crore for the fourth quarter of 2018-19 fiscal.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)